Results 1 to 10 of about 5,297,421 (194)

Expert consensus on neoadjuvant treatment of breast cancer in China (2021 edition) [PDF]

Zhongguo aizheng zazhi, 2022
Neoadjuvant therapy has become one of the standard treatments in early breast cancer. In 2019, China breast cancer neoadjuvant therapy expert group discussed and expounded the purpose, indication, evaluation criteria, surgical operation principles and ...
Expert group of expert consensus on neoadjuvant treatment of breast cancer in China ( edition)
doaj   +1 more source

Neoadjuvant therapy in patients with locally advanced colon cancer [PDF]

Waike lilun yu shijian, 2022
It is still unclear about neoadjuvant therapy in patients with locally advanced colon cancer (LACC). This review summarized neoadjuvant chemotherapy, neoadjuvant chemotherapy combined with targeted therapy and combined radio-chemotherapy for the patients
XU Zifeng, ZONG Yaping, LU Aiguo
doaj   +1 more source

Neoadjuvant Therapy for Locally Advanced Esophageal Cancers

Frontiers in Oncology, 2022
Esophageal carcinoma is one of the most aggressive malignant diseases. At present, neoadjuvant chemotherapy and neoadjuvant chemoradiotherapy are regarded as the standard modalities for the treatments of locally advanced esophageal cancers based on ...
Runkai Huang, Zhenbin Qiu, Chunwen Zheng, Ruijie Zeng, Wanxian Chen, Simeng Wang, Enmin Li, Yiwei Xu, Yiwei Xu   +8 more
doaj   +1 more source

Neoadjuvant therapy for gallbladder cancer: current status and challenge [PDF]

Waike lilun yu shijian, 2023
Gallbladder cancer is one of highly malignant digestive system tumors with insidious symptoms, rapid progression, and poor prognosis. Although radical resective surgery is the only possible curative way for gallbladder cancer, most patients have lost the
XING Ying, CHENG Shi
doaj   +1 more source

Evaluation of the efficacy and surgical-related safety of neoadjuvant immunochemotherapy in advanced resectable none small cell lung cancer (NSCLC)

Frontiers in Oncology, 2023
BackgroundThe emergence of immune checkpoint inhibitors (ICIs) has brought about a paradigm shift in the treatment landscape of non-small cell lung cancer (NSCLC).
Qin Wang, Chen Qi, Jing Luo, Nan Xu, Mao-tian Xu, Yong Qiang, Chi Zhang, Yi Shen   +7 more
doaj   +1 more source

Association between pathologic response and survival after neoadjuvant therapy in lung cancer

Nature Medicine, 2023
Analysis of the phase 3 CheckMate 816 trial shows that the depth of pathologic response as assessed by percent residual viable tumor is correlated with event-free survival following neoadjuvant immunotherapy plus chemotherapy, supporting pathologic ...
J. Deutsch, A. Cimino-Mathews, Elizabeth Thompson, Mariano Provencio, P. Forde, J. Spicer, N. Girard, Daphne Wang, Robert A Anders, Edward Gabrielson, Peter B Illei, J. Jedrych, Ludmila Danilova, J. Sunshine, Keith M Kerr, Mia Tran, J. Bushong, Junliang Cai, V. Devas, J. Neely, D. Balli, T. Cottrell, Alexander S. Baras, J. Taube   +23 more
semanticscholar   +1 more source

Neutrophil gelatinase-associated lipocalin (NGAL) predicts response to neoadjuvant chemotherapy and clinical outcome in primary human breast cancer [PDF]

, 2012
In our previous work we showed that NGAL, a protein involved in the regulation of proliferation and differentiation, is overexpressed in human breast cancer (BC) and predicts poor prognosis.
Arnold, Norbert, Ataseven, Beyhan, Bauer, Maret, Darb-Esfahani, Silvia, Denkert, Carsten Michael, Hamann, Sigrid, Holzhausen, Hans-Jürgen, Jonat, Walter, Khandan, Fariba, Loibl, Sibylle, Mehta, Keyur, Minckwitz, Gunther von, Mundhenke, Christoph, Müller, Berit, Park, Hyerim, Schem, Christian, Thomssen, Christoph, Weimer, Joerg, Wenners, Antonia Sophie   +18 more
core   +14 more sources

Neoadjuvant therapy with Disitamab vedotin in treating muscle-invasive bladder cancer: A case report

Heliyon, 2023
Purpose: Platinum-based regimens are regarded as the preferred alternative for neoadjuvant chemotherapy for muscle-invasive bladder cancer (MIBC) patients. However, some patients cannot tolerate platinum-based regimens. We report an MIBC case with severe
Haijun Huang, Yucong Zhang, Zhi Chen, Xing Zeng, Zhiquan Hu, Chunguang Yang   +5 more
doaj   +1 more source

Neoadjuvant therapy with immune checkpoint blockade, antiangiogenesis, and chemotherapy for locally advanced gastric cancer

Nature Communications, 2023
Immune checkpoint inhibitors and antiangiogenic agents have shown some activity in patients with late-stage gastric cancer. Here the authors report the results of a phase II trial of neoadjuvant anti-PD1 (camrelizumab), antiangiogenic agent (apatinib ...
Song Li, Wenbin Yu, Fei Xie, Haitao Luo, Zhimin Liu, Weiwei Lv, Duan-bo Shi, Dexin Yu, P. Gao, Cheng Chen, Meng Wei, Wenhao Zhou, Jiaqian Wang, Zhikun Zhao, Xin Dai, Qian Xu, Xue Zhang, Miao Huang, Kai Huang, Jian Wang, Jisheng Li, Lei Sheng, Lian Liu   +22 more
semanticscholar   +1 more source

Impact on CD4+ CD25High-CD127low regulatory T (Treg) cells of neoadjuvant therapy for rectal cancer patients

Indian Journal of Pathology and Microbiology, 2023
Background: The efficacy of neoadjuvant therapy for rectal cancer has not been assessed. Objective: To evaluate proportional changes in peripheral blood immune cells in rectal cancer patients after neoadjuvant therapy and assess the relationship between ...
Liu Maoxi, Liu Haiyi
doaj   +1 more source